Objective:To explore the mechanism and related active components of Yishen Daluo decoction(YSDLD)in treating multiple sclerosis(MS).Methods:Targets of YSDLD were collected through the TCMSP,Chemistry,and TCMID databas...Objective:To explore the mechanism and related active components of Yishen Daluo decoction(YSDLD)in treating multiple sclerosis(MS).Methods:Targets of YSDLD were collected through the TCMSP,Chemistry,and TCMID databases.The MS targets were collected through OMIM,DrugBank,Gencards,TTD,and Pharmgkb databases.We built“componentetarget”network diagrams and proteineprotein interaction(PPI)diagrams and performed topological analysis.The targets were subjected to GO and KEGG enrichment analysis.Molecular docking verification was conducted on selected targets and molecules.Finally,in vitro experiments were con-ducted.BV2 cells were induced by lipopolysaccharide for model establishment.CCK8 experiment was conducted to explore the effect of YSDLD and RT-qPCR technology was used to explore the expression of key targets.Results:There were 184 active components in YSDLD and 898 targets of its action.There were 940 MS targets,and 215 targets were shared by YSDLD and MS.According to the“componentetarget”diagram,the top five key components included quercetin,kaempferol,beta-sitosterol,stigmasterol,and nar-ingenin.IL-6,IL-1 b,TNF-α,AKT1,and VEGFA were the important targets identified by PPI network to-pology analysis.A total of 564 functions were identified by GO enrichment analysis(P<0.01),mainly involving inflammatory response,hypoxia response,plasma membrane,neuronal cell body,protein phosphatase binding,and cytokine activity.KEGG enrichment analysis enriched 98 pathways(P<.01).YSDLD at the concentration of 20 m g/mL had no effect on BV2 cells.RT-qPCR indicated that YSDLD at the concentrations of 15 m g/mL and 20 m g/mL alleviated LPS-induced inflammatory injury and lowered the content of inflammatory factors(P<0.05).Conclusion:In this paper,the network pharmacology and in vitro experiments were used to explore the potential mechanism of YSDLD in treating MS.The research provides a good basis for the development of YSDLD and drugs for MS in future.展开更多
Objective:To observe the effect of tetradecylene naphthalene soft capsule combined with Yishen Gubenyutong Decoction on bone metabolism and bone turnover in patients with osteoporosis and its clinical efficacy.Methods...Objective:To observe the effect of tetradecylene naphthalene soft capsule combined with Yishen Gubenyutong Decoction on bone metabolism and bone turnover in patients with osteoporosis and its clinical efficacy.Methods:A total of 100 patients with primary osteoporosis(all were treated by our hospital from February 2017 to June 2018)were divided into two groups.The control group(50 cases)was given to menatetrenone capsules.Treatment,observation group(50 cases)combined with Yishen Gubenqiaotongtong on the basis of the treatment of the control group,6 months for a course of treatment.The bone metabolic markers,bone mineral density changes and clinical efficacy were measured before and after treatment.Results:The total effective rate of the observation group was higher than that of the control group.After treatment,the observation group showed serum calcium(Ca),serum alkaline phosphatase(ALP)and typeⅠcollagen.The level of cross-linked C-terminal peptide(CTX-1)was lower than that of the control group.After treatment,the osteocalcin(OC)in the observation group was higher than that in the control group,and the bone mineral density(BMD)of lumbar vertebrae L2-4,femoral neck and femur trochanter in the observation group were higher than those in the control group.Conclusion:Menatetrenone soft capsule combined with Yishen Gubenyutong Decoction has good clinical effect on osteoporosis patients and it is worth further promotion in clinic.展开更多
目的评价蠲毒化浊益肾汤预防年轻乳腺癌患者化疗相关卵巢功能损伤的效果。方法63例经病理确诊的年轻乳腺癌患者,采用随机数字表法分为治疗组(31例)和对照组(32例)。对照组采用单纯化疗,治疗组化疗期间联合蠲毒化浊益肾汤口服。比较两组...目的评价蠲毒化浊益肾汤预防年轻乳腺癌患者化疗相关卵巢功能损伤的效果。方法63例经病理确诊的年轻乳腺癌患者,采用随机数字表法分为治疗组(31例)和对照组(32例)。对照组采用单纯化疗,治疗组化疗期间联合蠲毒化浊益肾汤口服。比较两组化疗后月经情况,化疗后围绝经期症状,血清雌二醇(E_(2))、卵泡刺激素(FSH)水平及低抗苗勒管激素(AMH)发生率。结果治疗组化疗后月经正常率29.03%,月经减少率54.84%,闭经率16.13%;对照组化疗后月经正常率12.50%,月经减少率43.75%,闭经率43.75%。两组化疗后月经变化情况比较差异有统计学意义(P<0.05)。治疗组闭经患者化疗后(4.40±1.14)个月发生闭经晚于对照组的(2.50±0.94)个月,具有显著性差异(P<0.05)。化疗后,治疗组22.58%患者出现围绝经期症状,对照组50.00%患者出现围绝经期症状;两组化疗后有围绝经期症状患者占比有统计学差异(P<0.05)。化疗前治疗组和对照组血清E_(2)[(49.65±15.27)pg/ml VS(46.06±12.99)pg/ml]、FSH[(6.15±1.78)U/L VS (5.93±1.55)U/L]比较均无统计学差异(P>0.05)。化疗后6个月治疗组血清E_(2)水平为(27.01±7.89)pg/ml,血清FSH水平为(21.94±10.54)U/L;对照组血清E_(2)水平为(19.64±8.55)pg/ml,血清FSH水平为(32.91±17.81)U/L。治疗组血清E_(2)下降水平少于对照组,血清FSH上升水平少于对照组,差异有统计学意义(P<0.05)。治疗组化疗后1年低AMH发生率35.48%(11/31),对照组化疗后1年低AMH发生率62.50%(20/32),两组比较差异具有统计学意义(χ^(2)=4.598,P=0.032<0.05)。结论年轻乳腺癌患者化疗期间服用蠲毒化浊益肾汤对卵巢功能具有保护作用,可减少月经紊乱及闭经的发生率、围绝经期症状的发生率及血清低AMH发生率,抑制血清E_(2)下降及FSH上升。展开更多
目的探讨益肾泄浊方对腺嘌呤所致的肾纤维化大鼠的作用及其机制。方法66只大鼠随机分为空白组、模型组、尿毒清组(1.6 g/kg)、益肾泻浊方低剂量组(0.65 g/kg)、益肾泻浊方中剂量组(1.3 g/kg)、益肾泻浊方高剂量组(2.6 g/kg),每组各11只...目的探讨益肾泄浊方对腺嘌呤所致的肾纤维化大鼠的作用及其机制。方法66只大鼠随机分为空白组、模型组、尿毒清组(1.6 g/kg)、益肾泻浊方低剂量组(0.65 g/kg)、益肾泻浊方中剂量组(1.3 g/kg)、益肾泻浊方高剂量组(2.6 g/kg),每组各11只。除空白组外,其余各组采用腺嘌呤(200 mg/kg)灌胃28 d诱导肾纤维化大鼠模型,造模后,尿毒清组和益肾泄浊方组给药治疗8周。测定SCr和BUN含量、24 h UTP和24 h mAlb水平;HE和Masson染色镜下观察肾脏组织病理变化;免疫组化测大鼠肾脏组织分泌型糖蛋白(Wnt1)、β-连环蛋白(β-catenin)的蛋白表达情况。结果与空白组比较,模型组、尿毒清组、低剂量组、中剂量组和高剂量组24 h UTP和24 h mAlb、SCr和BUN含量、Wnt1和β-catenin蛋白表达均升高(P<0.05);与模型组比较,尿毒清组、低剂量组、中剂量组和高剂量组24 h UTP和24 h mAlb、SCr和BUN水平、Wnt1和β-catenin蛋白表达均降低(P<0.05);与尿毒清组比较,低剂量组24 h UTP和24 h mAlb、SCr和BUN水平差异无统计学意义(P>0.05),Wnt1和β-catenin蛋白表达均降低(P<0.05),中剂量组和高剂量组24 h UTP和24 h mAlb、SCr和BUN水平、Wnt1和β-catenin蛋白表达均降低(P<0.05);与低剂量组比较,中剂量组和高剂量组24 h UTP和24 h mAlb、SCr和BUN水平、Wnt1和β-catenin蛋白表达均降低(P<0.05);与中剂量组比较,高剂量组24 h UTP和24 h mAlb、SCr和BUN水平、Wnt1和β-catenin蛋白表达均降低(P<0.05)。结论益肾泄浊方能够通过调控Wnt/β-catenin信号通路来阻抑肾纤维化的发展,从而起到保护肾脏的作用。展开更多
基金This work was supported by the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chi-nese Medicine(ZYYCXTD-C-202006).
文摘Objective:To explore the mechanism and related active components of Yishen Daluo decoction(YSDLD)in treating multiple sclerosis(MS).Methods:Targets of YSDLD were collected through the TCMSP,Chemistry,and TCMID databases.The MS targets were collected through OMIM,DrugBank,Gencards,TTD,and Pharmgkb databases.We built“componentetarget”network diagrams and proteineprotein interaction(PPI)diagrams and performed topological analysis.The targets were subjected to GO and KEGG enrichment analysis.Molecular docking verification was conducted on selected targets and molecules.Finally,in vitro experiments were con-ducted.BV2 cells were induced by lipopolysaccharide for model establishment.CCK8 experiment was conducted to explore the effect of YSDLD and RT-qPCR technology was used to explore the expression of key targets.Results:There were 184 active components in YSDLD and 898 targets of its action.There were 940 MS targets,and 215 targets were shared by YSDLD and MS.According to the“componentetarget”diagram,the top five key components included quercetin,kaempferol,beta-sitosterol,stigmasterol,and nar-ingenin.IL-6,IL-1 b,TNF-α,AKT1,and VEGFA were the important targets identified by PPI network to-pology analysis.A total of 564 functions were identified by GO enrichment analysis(P<0.01),mainly involving inflammatory response,hypoxia response,plasma membrane,neuronal cell body,protein phosphatase binding,and cytokine activity.KEGG enrichment analysis enriched 98 pathways(P<.01).YSDLD at the concentration of 20 m g/mL had no effect on BV2 cells.RT-qPCR indicated that YSDLD at the concentrations of 15 m g/mL and 20 m g/mL alleviated LPS-induced inflammatory injury and lowered the content of inflammatory factors(P<0.05).Conclusion:In this paper,the network pharmacology and in vitro experiments were used to explore the potential mechanism of YSDLD in treating MS.The research provides a good basis for the development of YSDLD and drugs for MS in future.
基金Scientific Research Project of Guangdong Traditional Chinese Medicine Bureau(20191292).
文摘Objective:To observe the effect of tetradecylene naphthalene soft capsule combined with Yishen Gubenyutong Decoction on bone metabolism and bone turnover in patients with osteoporosis and its clinical efficacy.Methods:A total of 100 patients with primary osteoporosis(all were treated by our hospital from February 2017 to June 2018)were divided into two groups.The control group(50 cases)was given to menatetrenone capsules.Treatment,observation group(50 cases)combined with Yishen Gubenqiaotongtong on the basis of the treatment of the control group,6 months for a course of treatment.The bone metabolic markers,bone mineral density changes and clinical efficacy were measured before and after treatment.Results:The total effective rate of the observation group was higher than that of the control group.After treatment,the observation group showed serum calcium(Ca),serum alkaline phosphatase(ALP)and typeⅠcollagen.The level of cross-linked C-terminal peptide(CTX-1)was lower than that of the control group.After treatment,the osteocalcin(OC)in the observation group was higher than that in the control group,and the bone mineral density(BMD)of lumbar vertebrae L2-4,femoral neck and femur trochanter in the observation group were higher than those in the control group.Conclusion:Menatetrenone soft capsule combined with Yishen Gubenyutong Decoction has good clinical effect on osteoporosis patients and it is worth further promotion in clinic.
文摘目的评价蠲毒化浊益肾汤预防年轻乳腺癌患者化疗相关卵巢功能损伤的效果。方法63例经病理确诊的年轻乳腺癌患者,采用随机数字表法分为治疗组(31例)和对照组(32例)。对照组采用单纯化疗,治疗组化疗期间联合蠲毒化浊益肾汤口服。比较两组化疗后月经情况,化疗后围绝经期症状,血清雌二醇(E_(2))、卵泡刺激素(FSH)水平及低抗苗勒管激素(AMH)发生率。结果治疗组化疗后月经正常率29.03%,月经减少率54.84%,闭经率16.13%;对照组化疗后月经正常率12.50%,月经减少率43.75%,闭经率43.75%。两组化疗后月经变化情况比较差异有统计学意义(P<0.05)。治疗组闭经患者化疗后(4.40±1.14)个月发生闭经晚于对照组的(2.50±0.94)个月,具有显著性差异(P<0.05)。化疗后,治疗组22.58%患者出现围绝经期症状,对照组50.00%患者出现围绝经期症状;两组化疗后有围绝经期症状患者占比有统计学差异(P<0.05)。化疗前治疗组和对照组血清E_(2)[(49.65±15.27)pg/ml VS(46.06±12.99)pg/ml]、FSH[(6.15±1.78)U/L VS (5.93±1.55)U/L]比较均无统计学差异(P>0.05)。化疗后6个月治疗组血清E_(2)水平为(27.01±7.89)pg/ml,血清FSH水平为(21.94±10.54)U/L;对照组血清E_(2)水平为(19.64±8.55)pg/ml,血清FSH水平为(32.91±17.81)U/L。治疗组血清E_(2)下降水平少于对照组,血清FSH上升水平少于对照组,差异有统计学意义(P<0.05)。治疗组化疗后1年低AMH发生率35.48%(11/31),对照组化疗后1年低AMH发生率62.50%(20/32),两组比较差异具有统计学意义(χ^(2)=4.598,P=0.032<0.05)。结论年轻乳腺癌患者化疗期间服用蠲毒化浊益肾汤对卵巢功能具有保护作用,可减少月经紊乱及闭经的发生率、围绝经期症状的发生率及血清低AMH发生率,抑制血清E_(2)下降及FSH上升。
文摘目的探讨益肾泄浊方对腺嘌呤所致的肾纤维化大鼠的作用及其机制。方法66只大鼠随机分为空白组、模型组、尿毒清组(1.6 g/kg)、益肾泻浊方低剂量组(0.65 g/kg)、益肾泻浊方中剂量组(1.3 g/kg)、益肾泻浊方高剂量组(2.6 g/kg),每组各11只。除空白组外,其余各组采用腺嘌呤(200 mg/kg)灌胃28 d诱导肾纤维化大鼠模型,造模后,尿毒清组和益肾泄浊方组给药治疗8周。测定SCr和BUN含量、24 h UTP和24 h mAlb水平;HE和Masson染色镜下观察肾脏组织病理变化;免疫组化测大鼠肾脏组织分泌型糖蛋白(Wnt1)、β-连环蛋白(β-catenin)的蛋白表达情况。结果与空白组比较,模型组、尿毒清组、低剂量组、中剂量组和高剂量组24 h UTP和24 h mAlb、SCr和BUN含量、Wnt1和β-catenin蛋白表达均升高(P<0.05);与模型组比较,尿毒清组、低剂量组、中剂量组和高剂量组24 h UTP和24 h mAlb、SCr和BUN水平、Wnt1和β-catenin蛋白表达均降低(P<0.05);与尿毒清组比较,低剂量组24 h UTP和24 h mAlb、SCr和BUN水平差异无统计学意义(P>0.05),Wnt1和β-catenin蛋白表达均降低(P<0.05),中剂量组和高剂量组24 h UTP和24 h mAlb、SCr和BUN水平、Wnt1和β-catenin蛋白表达均降低(P<0.05);与低剂量组比较,中剂量组和高剂量组24 h UTP和24 h mAlb、SCr和BUN水平、Wnt1和β-catenin蛋白表达均降低(P<0.05);与中剂量组比较,高剂量组24 h UTP和24 h mAlb、SCr和BUN水平、Wnt1和β-catenin蛋白表达均降低(P<0.05)。结论益肾泄浊方能够通过调控Wnt/β-catenin信号通路来阻抑肾纤维化的发展,从而起到保护肾脏的作用。
